BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
IMCR upcoming catalysts
Immunocore Ltd: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to IMCR (.ics).
Drugs: IMC-R117C, Kinase inhibitor, Antiangiogenic Agent, Monoclonal antibody, pembrolizumab, bevacizumab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | Immunocore Ltd IMCR | NCT06840119 Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Cancer; HLA-A*02:01-positive | recruiting | 600 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P1/P2 | Immunocore Ltd IMCR | NCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Select Advanced Solid Tumors | active not recruiting | 410 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.